Loading clinical trials...
Loading clinical trials...
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ADARx Pharmaceuticals, Inc.
NCT06960213 · Hereditary Angioedema, HAE, and more
NCT07298447 · Hereditary Angioedema (HAE)
NCT06842823 · Hereditary Angioedema (HAE)
NCT07046806 · Hereditary Angioedema (HAE), Angioedema, and more
NCT05396105 · Hereditary Angioedema, Hereditary Angioedema Type I, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions